TMS for Long COVID Depression, Fatigue and Brain Fog

For long COVID, TMS evidence is early and limited to case series, small open-label pilots and retrospective clinic data; the authors of that work say randomized trials are needed. Using TMS to treat long COVID fatigue or brain fog is off-label and research-stage, and no TMS device is FDA-cleared for long COVID.

Depression that develops or persists after COVID is a different matter. If it meets criteria for major depressive disorder and has not improved with antidepressants, it can be treated with TMS under the standard depression indication. One caution from recent clinic data: depression linked to long COVID may respond less well than typical depression.

What counts as long COVID

The World Health Organization describes post COVID-19 condition as a range of symptoms that usually start within three months of the initial illness and last at least two months. Common symptoms include fatigue, breathlessness, muscle or joint pain, headaches and difficulty thinking or concentrating; WHO estimates that about 6 in 100 people with COVID-19 develop the condition.

Mood and cognitive symptoms are part of that picture, but they overlap heavily with other causes. Fatigue, poor sleep, deconditioning, autonomic problems, medication effects and the stress of a long illness can all produce low mood and fogginess. Separating a true major depressive episode from these is the first clinical task.

The evidence so far

The largest comparison is the most sobering. In the 2026 Tokyo cohort, MADRS improvement averaged 38.4% in long COVID-associated depression versus 61.5% in matched patients with primary depression, and remission on the Hamilton scale was 27.3% versus 61.4%. Response rates on the Hamilton scale did not differ significantly, and the authors stress that a retrospective design can show an association, not a cause. Still, it is the best available hint that long COVID depression may not behave like ordinary depression. The difference between response and remission is explained in response vs remission.

Why long COVID depression might respond differently

Researchers have proposed several reasons. Long COVID has been linked to persistent neuroinflammation, endothelial dysfunction and disrupted fronto-limbic networks, features that differ from typical major depression. If low mood is partly a downstream effect of an ongoing medical process, stimulating the prefrontal cortex may relieve only part of it. Ongoing fatigue and pain can also keep depression scores elevated even when mood itself improves.

These are hypotheses, not conclusions. They do argue for measuring outcomes carefully, setting expectations honestly, and treating medical contributors in parallel rather than relying on TMS alone. Factors that predict response more generally are reviewed in who responds to TMS.

Depression after COVID: treat it as depression

When long COVID comes with a genuine major depressive episode, the evidence base for depression applies. That means the usual sequence: careful diagnosis, psychotherapy and an adequate antidepressant trial, and then, if those have not worked, treatment-resistant options. The Canadian CANMAT 2023 guideline rates rTMS a first-line option for treatment-resistant depression. TMS is assessed for a person with long COVID exactly as for anyone else with depression, with extra attention to the medical picture.

That medical picture matters because long COVID depression may have contributors that ordinary antidepressant pathways do not reach. Persistent inflammation is one candidate under study, discussed in inflammation and treatment-resistant depression. A review of thyroid function, iron and vitamin levels, sleep and medications belongs in every workup, as described in ruling out medical causes before TMS.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Fatigue and brain fog: why TMS is not yet an answer

For fatigue and cognitive complaints without major depression, no adequately sized sham-controlled trial shows that TMS helps; the only sham-controlled report is the four-person case series above. There are also practical reasons for caution.

• The schedule is demanding. A standard course means five clinic visits a week for six weeks, then a taper, 36 sessions in all. For someone whose symptoms worsen after exertion, travel and sessions can be a real cost.
• Accelerated protocols compress many sessions into a few days. In the SAINT data reviewed by FDA, fatigue was reported by 57% of the active group, a side effect that matters for people already limited by exhaustion. The trade-offs are covered in accelerated TMS.
• Brain fog is not one thing. Attention, processing speed and memory problems can stem from sleep disruption, autonomic dysfunction, mood or medication, and each calls for a different response.

Rehabilitation approaches paced to avoid post-exertional crashes, sleep treatment, and management of specific problems such as orthostatic intolerance remain the backbone of care. The site's fatigue treatment page describes a broader evaluation.

Safety considerations

TMS is generally safe, and seizure is rare under standard protocols. Some factors relevant to people recovering from infection lower the seizure threshold, including systemic infection, fever, sleep deprivation and metabolic disturbances such as low sodium or abnormal blood glucose. Starting a course during an active infection or a significant flare is unwise. The full safety picture is in TMS safety and seizure risk.

Coverage

Insurance coverage for TMS is tied to major depressive disorder. Medicare in New York, for example, considers TMS medically necessary only for adults with a confirmed MDD diagnosis who meet its treatment-history criteria. Long COVID itself is not a covered indication, so documentation should reflect the depression diagnosis and the treatments already tried. Details are in the Medicare coverage guide.

Questions to ask before TMS for long COVID symptoms

1. Do I meet criteria for major depression, or are my symptoms mainly fatigue and cognitive problems?
2. Have medical contributors been checked and treated?
3. Have I had an adequate trial of psychotherapy and medication for the depression?
4. Can I manage daily sessions without triggering a crash, and is a shorter schedule safe for me?
5. How will we measure progress, and when would we stop if there is no benefit?

The honest status today: TMS is a reasonable option for treatment-resistant depression in someone with long COVID, possibly with lower odds of remission than usual, and an unproven one for the fatigue and fog that define the condition. For the basics of TMS, see the TMS guide and the TMS overview.

Frequently asked questions

Is TMS FDA-cleared for long COVID?

No. TMS is cleared for major depressive disorder and a few other conditions. Using it for long COVID fatigue or brain fog is off-label and research-stage.

Can TMS treat depression that started after COVID?

Yes, if it meets criteria for major depression and has not improved with standard treatment. A 2026 retrospective study suggests it may respond less well than typical depression, so expectations should be realistic.

Will TMS help my brain fog?

There is no reliable sham-controlled evidence that it does; the only sham-controlled report involved four people. Brain fog in long COVID has many possible causes, including sleep problems, autonomic dysfunction and mood, which call for a broader evaluation.

Could TMS make long COVID fatigue worse?

Daily sessions are demanding, and fatigue is a reported side effect of some accelerated protocols. People prone to post-exertional crashes should plan the schedule carefully with their clinicians.

Does insurance cover TMS for long COVID?

Coverage applies to major depressive disorder that meets each plan's criteria, not to long COVID itself.

Sources

1. FDA 510(k) K160703 and K161519. U.S. FDA, 2016. accessdata.fda.gov
2. K231926 510(k) Summary. U.S. FDA, 2024. accessdata.fda.gov
3. K220177 510(k) Summary. U.S. FDA, 2022. accessdata.fda.gov
4. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
5. Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan. Asian Journal of Psychiatry, 2023. europepmc.org
6. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry, 2024. pmc.ncbi.nlm.nih.gov
7. LCD L33398 Transcranial Magnetic Stimulation (version 40). Wellpoint Federal (formerly National Government Services) via CMS Medicare Coverage Database / CMS Coverage API, 2026. cms.gov
8. Post COVID-19 condition (long COVID) fact sheet. World Health Organization, 2025. who.int
9. rTMS for post-covid-19 condition: A sham-controlled case series involving iTBS-300 and iTBS-600. Brain, Behavior, & Immunity - Health, 2024. europepmc.org
10. Cognitive and Psychological Symptoms in Post-COVID-19 Condition: A Systematic Review of Structural and Functional Neuroimaging, Neurophysiology, and Intervention Studies. Archives of Rehabilitation Research and Clinical Translation, 2025. europepmc.org
11. Comparative Treatment Response to Intermittent Theta Burst Stimulation in Long COVID-Associated Depression Versus Major Depressive Disorder: A Propensity Score-Matched Retrospective Cohort Study. Biomedicines, 2026. europepmc.org

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.